📅 PUBMED DAILY TRIAGE — 2026-06-08

Window: 2026-06-07T09:00:00Z → 2026-06-08T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~65 candidates | Records classified: 15 High priority: 3 | Standard: 12 | Low/archive: ~14 | Unsolicited finds: 1 Run status: SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk

TR-2026-06-08-001 / PMID 42252247 · GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults · 9/10 · First large-scale study (n=229K, target trial emulation, Ann Oncol) showing GLP-1RAs reduce obesity-associated cancer incidence by 41% (HR 0.59) in nondiabetic obese adults — a novel prevention signal across cancer types with one notable race-disparity exception.

TR-2026-06-08-002 / PMID 42252333 · Survodutide in adults with obesity and MASLD: SYNCHRONIZE-MASLD phase 3 RCT · 9/10 · Double-blind RCT (Nature Medicine) demonstrates survodutide (novel glucagon/GLP-1 dual agonist) achieved ≥30% liver fat reduction in 84.2% vs 24.3% placebo and -12.2% vs -1.0% body weight change at 48 weeks — a potentially practice-changing result for MASLD.

Rare diseases with high unmet need

TR-2026-06-08-003 / PMID 42252093 · Septin multimer autoantibodies in severe motor neuropathy mimicking lower motor neuron disease · 8/10 · Multi-institutional discovery paper (Brain, n=3,543 screened) identifies septin multimers as novel autoantibody targets in ALS-mimicking neuropathy, with validated target specificity and disease stabilization on immunotherapy — clinically critical treatable-vs-fatal distinction.

🟢⚪ STANDARD (5-7) — Top by Topic

Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma)

• TR-2026-06-08-004 / PMID 42252425 · High-risk cytogenetics in CBF-AML case-control study · 7/10 · Genomics/Precision Medicine
• TR-2026-06-08-005 / PMID 42252503 · Cancer prevalence in Down Syndrome (n=5,895, 24yr EHR) · 7/10 · Public Health / UNDERSERVED_POPULATION

Precision oncology and genomic medicine

• TR-2026-06-08-006 / PMID 42252502 · HER2-mutant NSCLC real-world France (n=18,069) — only 41.7% tested, 18.6 mo mOS · 7/10 · Diagnostics / NEAR_TERM_IMPLEMENTABLE

Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk (continued)

• TR-2026-06-08-007 / PMID 42252120 · GLP-1RA use in Danish adolescents/young adults 2018-2025 (50-fold increase, 33% psychiatric comorbidity) · 7/10 · Public Health / UNDERSERVED_POPULATION
• TR-2026-06-08-009 / PMID 42252454 · GLP-1RA + SGLT2i combination in cardiometabolic disease review · 6/10 · Treatment Innovation
• TR-2026-06-08-011 / PMID 42252499 · BIOMAG-I bioresorbable Mg scaffold in high-risk coronary plaques (n=83) · 5/10 · Treatment Innovation

Early cancer detection (liquid biopsy, ctDNA, cfDNA)

• TR-2026-06-08-008 / PMID 42250371 (deferred) · Multi-omic biomarkers neoadjuvant rectal cancer review (KU Leuven) · 6/10 · Early Detection
• TR-2026-06-08-013 / PMID 42251925 · Gasdermin proteins as pyroptosis-based liquid biopsy biomarkers in ovarian cancer · 5/10 · Early Detection
• TR-2026-06-08-014 / PMID 42250735 (deferred) · CircRNA/miRNA/ABCC1 MDR axis review with liquid biopsy biomarker angle · 5/10 · Drug Development
• TR-2026-06-08-015 / PMID 42250175 (deferred) · Multi-omics + liquid biopsy integration in breast cancer review · 5/10 · Early Detection

Novel therapeutics: immunotherapy, CAR-T, targeted therapy

• TR-2026-06-08-010 / PMID 42252404 · RHPI+CAG risk prediction nomogram (AUC 0.833, n=367) (unsolicited find) · 6/10 · Early Detection
• TR-2026-06-08-012 / PMID 42252409 · Macrophage heterogeneity in PD-1/PD-L1 inhibitor therapy (scRNA-seq review) · 5/10 · Treatment Innovation

Aging, longevity, and population health

(No high-priority finds today — topic: 0/10, best candidate score: N/A)

AI/ML in clinical diagnostics and imaging

(No high-priority finds today — best candidate scored 4/10)

CBC-based diagnostics and ML in hematology

(No high-priority finds today — 1 raw result, score ≤4)

💡 UNSOLICITED FINDS

• TR-2026-06-08-010 / PMID 42252404 · RHPI+CAG nomogram (n=367, AUC 0.833) — gastric cancer precursor risk stratification, outside core watchlist. Score 6/10, kept for gastric precancer clinical relevance.

📊 TODAY'S BREAKDOWN

By research category:

• Treatment Innovation: 4 (TR-001, TR-002, TR-011, TR-012)
• Early Detection: 5 (TR-008, TR-010, TR-013, TR-014, TR-015)
• Diagnostics: 3 (TR-004, TR-006, TR-009)
• Public Health: 3 (TR-005, TR-007, TR-009)
• Drug Development: 1 (TR-014)
• Genomics/Precision Medicine: 1 (TR-004)

By evidence maturity:

• Potentially Practice-Changing: 1 (TR-002 — Survodutide phase 3)
• Validated: 6 (TR-001, TR-004, TR-005, TR-006, TR-007, TR-009)
• Exploratory: 8 (TR-003, TR-008, TR-010–TR-015)

By watchlist topic (reviewed / kept / highest score):

By source type: peer_reviewed 15 | preprint 0

Topics with zero 8+ articles this run: T1, T2, T3, T4, T5, T6, T8

🔧 RUN NOTES

• T8 (Aging/longevity): 0 results for 3rd+ consecutive run with humans[MeSH] filter. The filter is eliminating too many valid human aging articles. Recommendation for next run: Replace humans[MeSH] with (clinical OR cohort OR patient OR longitudinal) as scoping qualifier — less restrictive, avoids MeSH indexing lag on new records.

• T2 (CBC/ML hematology): 1 raw result again (4th consecutive day ≤1 result). Expanded query with morphology/cytology broadening did recover 1 result. Query is working; volume simply reflects sparse indexing overlap. No further changes recommended immediately.

• 3 deferred PMIDs (42250735, 42250371, 42250175) from 2026-06-07 batch truncation successfully retrieved and classified in this run as STANDARD (scores 5-6). No HIGH articles among deferred set.

• Batch truncation: ~20 additional candidate articles were identified from esearch IDs but not fully retrieved due to cumulative 20KB XML response truncation per efetch call. These were assessed from metadata/title only and classified LOW. The HIGH-priority articles were prioritized in sequential fetch batches and all HIGH candidates are confirmed as fully reviewed.

• Rolling 7-day view — topics consistently 0 HIGH articles:

  • T2 (CBC/ML hematology): 0 HIGH for 7+ consecutive days. Expected sparse topic.
  • T8 (Aging/longevity): 0 HIGH for ~2 weeks. Filter issue confirmed; fix recommended above.
  • T4 (AI/ML diagnostics): 1 HIGH in last 7 days (prior run). Today: 0.

• T7 (Cardiovascular-metabolic) continues as strongest daily signal topic. Two 9/10 articles today — one RCT in Nature Medicine (Survodutide) and one large pharmacoepidemiology study (GLP-1RA cancer prevention). GLP-1/SGLT2 literature pipeline remains extremely active.

• Novel finding today: GLP-1RA cancer prevention finding (TR-001, n=229K) combined with Survodutide MASLD phase 3 (TR-002) makes this an exceptionally strong T7 day — both likely to have downstream Phase 2 pipeline impact.